Summary of Study ST001515
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001022. The data can be accessed directly via it's Project DOI: 10.21228/M8KT26 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST001515 |
Study Title | A Metabolomic Signature of Glucagon Action in Healthy Individuals with Overweight/Obesity Humans |
Study Summary | Objective: We sought to identify the circulating metabolites that would serve as markers of glucagon action. Design: In this study, we performed a continuous 72-hour glucagon infusion in healthy individuals with overweight/obesity. Participants were randomized to either glucagon (12.5 ng/kg/min) (GCG 12.5) or glucagon (25 ng/kg/min) GCG 25 or a placebo control were included. A comprehensive metabolomics analysis was then performed from plasma isolated at several time points during the infusion to identify markers of glucagon activity. |
Institute | Translational Research Institute- AdventHealth Orlando |
Last Name | Whytock |
First Name | Katie |
Address | 301 E Princeton St, Orlando, FL, 32804 |
Katie.Whytock@adventhealth.com | |
Phone | 321-945-9982 |
Submit Date | 2020-10-26 |
Num Groups | 3 |
Total Subjects | 33 |
Raw Data Available | Yes |
Analysis Type Detail | LC-MS |
Release Date | 2020-12-01 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001022 |
Project DOI: | doi: 10.21228/M8KT26 |
Project Title: | Effects of glucagon infusion on plasma metabolome in individuals with overweight/obesity |
Project Summary: | Objective: We sought to identify the circulating metabolites that would serve as markers of glucagon action. Design: In this study, we performed a continuous 72-hour glucagon infusion in healthy individuals with overweight/obesity. Participants were randomized to either glucagon (12.5 ng/kg/min) (GCG 12.5) or glucagon (25 ng/kg/min) GCG 25 or a placebo control were included. A comprehensive metabolomics analysis was then performed from plasma isolated at several time points during the infusion to identify markers of glucagon activity. |
Institute: | Translational Research Institute- AdventHealth Orlando |
Last Name: | Whytock |
First Name: | Katie |
Address: | 301 E Princeton St, FL, USA, 32804 |
Email: | Katie.Whytock@adventhealth.com |
Phone: | 3219459982 |
Funding Source: | Sanofi |